6-Chloro-2-methylspiro[2,3-dihydropyrano[2,3-b]pyridine-4,5'-imidazolidine]-2',4'-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 6-Chloro-2-methylspiro[2,3-dihydropyrano[2,3-b]pyridine-4,5'-imidazolidine]-2',4'-dione
• 化学式: C₁₁H₁₀ClN₃O₃
• 分子量: 267.67
• InChiKey: WFPFAWQUEPGPQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  80.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-Chloro-2-methylspiro[2,3-dihydropyrano[2,3-b]pyridine-4,5'-imidazolidine]-2',4'-dione 生成 (+)-cis-6'-chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]-2,5-dione
  参考文献：
  名称：

  GOLDSTEIN, STEVEN W.;SARGES, REINHARD

  摘要：

  DOI：
• 作为产物：
  描述：

  6-chloro-2,3-dihydro-2-methyl-4H-pyrano<2,3-b>pyridin-4-one 、 氰化钾 、 碳酸铵 、 sodium hydrogensulfite 生成 6-Chloro-2-methylspiro[2,3-dihydropyrano[2,3-b]pyridine-4,5'-imidazolidine]-2',4'-dione
  参考文献：
  名称：

  GOLDSTEIN, STEVEN W.;SARGES, REINHARD

  摘要：

  DOI：

文献信息

• Azolidinedione derivatives
  申请人：PFIZER INC.

  公开号：EP0306251A2

  公开（公告）日：1989-03-08

  A series of novel spiro-heteroazolones derived from a 2,3-dihydropyrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxazolidinediones, spiro-thiazolidinediones and spiroimidazolidinediones derived from the aforesaid ring system. (4'S)(2'R)-6'-Chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-py- rano[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.

  我们制备出了一系列新型螺杂环唑酮类化合物，它们来自 2,3-二氢吡喃并[2,3-b]吡啶环系统，包括其药学上可接受的盐类。这些化合物可作为醛糖还原酶抑制剂用于治疗，以控制某些慢性糖尿病并发症。典型的成员化合物包括由上述环系统衍生的螺烷基亚胺、螺烷基噁唑烷二酮、螺烷基噻唑烷二酮和螺烷基咪唑烷二酮。(4'S)(2'R)-6'-氯-2',3'-二氢-2'-甲基-螺-[咪唑烷-4,4'-4'H-吡喃并[2,3-b]吡啶]-2,5-二酮代表了一种典型的优选成员化合物。本文提供了用已知起始原料制备所有这些化合物的方法。
• GOLDSTEIN, STEVEN W.;SARGES, REINHARD
  作者：GOLDSTEIN, STEVEN W.、SARGES, REINHARD

  DOI：——

  日期：——
• SARGES, REINHARD;GOLDSTEIN, STEVEN W.;WELCH, WILLARD M.;SWINDELL, ARCHIE +, J. MED. CHEM., 33,(1990) N, C. 1859-1865
  作者：SARGES, REINHARD、GOLDSTEIN, STEVEN W.、WELCH, WILLARD M.、SWINDELL, ARCHIE +

  DOI：——

  日期：——
• US4980357A
  申请人：——

  公开号：US4980357A

  公开（公告）日：1990-12-25
• [EN] AZOLIDINEDIONE DERIVATIVES
  申请人：PFIZER INC.

  公开号：WO1989001775A1

  公开（公告）日：1989-03-09

  (EN) A series of novel $i(spiro)-heteroazolones derived form a 2,3-dihydropyrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include $i(spiro)-imides, $i(spiro)-oxazolidinediones, $i(spiro)-thiazolidinediones and $i(spiro)-imidazolidinediones derived from the aforesaid ring system. (4'$i(S)) (2'$i(R))-6'-chloro-2',3'-dihydro-2'-methyl-$i(spiro)-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.(FR) Une série de nouvelles $i(spiro)-hétéroazolones dérivées d'un système cyclique 2,3-dihydropyrano[2,3-b]pyridine ont été préparées, y compris leurs sels pharmaceutiquement acceptables. Ces composés sont utiles en thérapie en tant qu'inhibiteurs de réductase d'aldose pour le traitement de certaines complications diabétiques chroniques. Des composés membres typiques comprennent des $i(spiro)-imides, $i(spiro)-oxazolidinediones, des $i(spiro)-thiazolidinediones et des $i(spiro)-imidazolidinediones dérivées du système d'anneau susmentionné. (4'$i(S)) (2'$i(R))-6'-chloro-2',3'-dihydro-2'-méthyle-$i(spiro)-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]-2,5-dione représente un composé membre typique et préféré. Des procédés de préparation de tous ces composés à partir de substances de départ connues sont décrits.